A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers

• Drug: PF-04171327
  
  PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
• Drug: Prednisolone
  
  Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
• Drug: Placebo
  
  Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
• Drug: Placebo Solution
  
  Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
• Drug: PF-04171327 Tablet
  
  A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.

• Experimental: PF-04173127
  
  Intervention: Drug: PF-04171327
• Active Comparator: Prednisolone
  
  Intervention: Drug: Prednisolone
• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo
• Sham Comparator: Solution Placebo
  
  Intervention: Drug: Placebo Solution
• Experimental: PF-04171327 Tablet
  
  Intervention: Drug: PF-04171327 Tablet

Inclusion Criteria:

• Healthy males between 18 and 55 years, inclusive.
• Healthy females between 18 and 44 years, inclusive.

Exclusion Criteria:

• Evidence or history of clinically significant disease;
• Post-menopausal women;
• History of intolerance or significant adverse effects with glucocorticoids. therapy.